Finally, we observed the anti-CRC function of low-dose celastrol and SHP2 inhibition in xenograft animal models in vivo. Taken together, our findings highlighted that celastrol administration with SHP2 inhibition may present a promising molecular therapeutic strategy for CRC. This evidence concerns the gene PTPN11 and colorectal carcinoma.